CHRONIC MYELOGENOUS LEUKEMIA
Clinical trials for CHRONIC MYELOGENOUS LEUKEMIA explained in plain language.
Never miss a new study
Get alerted when new CHRONIC MYELOGENOUS LEUKEMIA trials appear
Sign up with your email to follow new studies for CHRONIC MYELOGENOUS LEUKEMIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New transplant drug combo shows promise for blood cancer patients
Disease control CompletedThis study tested a new way to prepare patients with blood cancers for a bone marrow transplant from a half-matched donor. Instead of using the standard drug cyclophosphamide after transplant, doctors replaced it with bendamustine to see if it was safer and still worked. About 50…
Matched conditions: CHRONIC MYELOGENOUS LEUKEMIA
Phase: PHASE1 • Sponsor: University of Arizona • Aim: Disease control
Last updated May 17, 2026 05:37 UTC
-
Half-Matched donor transplants offer hope for blood cancer patients
Disease control CompletedThis study tested a stem cell transplant from half-matched (haploidentical) family donors for people with various blood cancers. The treatment used a reduced-intensity chemotherapy and radiation regimen to prepare the body for the transplant. The goal was to see how many patients…
Matched conditions: CHRONIC MYELOGENOUS LEUKEMIA
Phase: PHASE2 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated May 17, 2026 05:36 UTC
-
Can a switch to a cheaper drug keep leukemia at bay?
Disease control CompletedThis study looked at whether people with chronic myeloid leukemia (CML) who achieved a good response to the drug nilotinib could safely switch to a different drug, imatinib, to maintain that response. The goal was to see if imatinib could keep the cancer under control while poten…
Matched conditions: CHRONIC MYELOGENOUS LEUKEMIA
Phase: NA • Sponsor: American University of Beirut Medical Center • Aim: Disease control
Last updated May 15, 2026 11:53 UTC
-
New pill shows promise for Hard-to-Treat leukemia patients
Disease control CompletedThis study tested an oral drug called asciminib in 199 adults with chronic myeloid leukemia (CML) whose cancer had not responded well to at least two previous treatments. The goal was to see how many patients achieved a major molecular response—a significant drop in leukemia-rela…
Matched conditions: CHRONIC MYELOGENOUS LEUKEMIA
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated May 14, 2026 12:04 UTC
-
Leukemia drug holiday: many patients stay in remission after stopping nilotinib
Disease control CompletedThis study looked at whether people with chronic myeloid leukemia (CML) who had a deep response to the drug nilotinib could safely stop taking it without the cancer coming back. 215 adults who had been on nilotinib for at least two years were enrolled. The main finding was that m…
Matched conditions: CHRONIC MYELOGENOUS LEUKEMIA
Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated May 07, 2026 18:38 UTC
-
New combo therapy aims to deepen remission in CML patients
Disease control CompletedThis study tested whether adding the experimental drug asciminib to the standard treatment imatinib helps people with chronic myeloid leukemia (CML) achieve a deeper molecular response (very low cancer levels). It included 104 adults who had been on imatinib for at least a year b…
Matched conditions: CHRONIC MYELOGENOUS LEUKEMIA
Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Apr 26, 2026 20:02 UTC